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Abstract
Background: There are no generally accepted guide-
lines for the prevention of venous thromboembolism
(VTE) in ambulatory patients requiring immobilization
after an isolated lower leg injury. Our objective was to
evaluate the effectiveness and safety of pharmacolog-
ical interventions for preventing VTE in these patients.
Study Design: Meta-analysis of randomized controlled
trials.
Materials and Methods: We searched PubMed/
Medline, EMBASE and the Cochrane Central Register of
Controlled Trials for trials with random allocation of
thromboprophylaxis, notably low molecular weight
heparin (LMWH) versus no prophylaxis or placebo, in
ambulatory patients with below-knee or lower leg
(including the knee joint) immobilization. Outcome was
analyzed using MIX to calculate the pooled risk ratio/
relative risk (RR) for each outcome, along with its 95%
confidence interval (CI).
Results: The RR of asymptomatic deep vein thrombosis
(DVT) was 0.66 (95% CI 0.44; 1.02) for below-knee
immobilization and 0.51 (95% CI 0.37; 0.70) for lower leg
immobilization. Low molecular weight heparin versus
no prophylaxis or placebo was evaluated. The incidence
of symptomatic DVT and PE was too low to show any
statistically significant difference between thrombo-
prophylaxis and controls in both groups. Although only
one adverse bleeding event was considered to be major,
the RR for any adverse bleeding event was 1.94 (95% CI
1.03; 3.67).
Conclusion: There is insufficient evidence to warrant
routine use of thromboprophylaxis in ambulatory
patients with below-knee or lower leg immobilization
after an isolated lower leg injury. The incidence of
symptomatic VTE is too low to show a relevant clinical
benefit from thromboprophylaxis.
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Background
Venous thromboembolism (VTE) is a common
complication in hospitalized bed-ridden patients
after major trauma and after hip arthroplasty [1, 2].
Thromboprophylaxis is therefore provided in most of
these patients. However, to date there are no gener-
ally accepted recommendations for the prevention of
VTE in ambulatory patients requiring below-knee or
lower leg (i.e., including the knee joint) immobiliza-
tion after an isolated lower leg injury. The reported
incidence of symptomatic deep vein thrombosis
(DVT) after lower leg injury varies substantially,
from 0.22% in patients operated on for foot or
ankle injuries [3] to 7.6% after surgical treatment of
Achilles tendon ruptures [4]. In a large cohort of
nonsurgical isolated limb injuries treated with below-
knee immobilization, an incidence of 1.0% was found
[7]. At the Seventh ACCP Conference on Anti-
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thrombotic and Thrombolytic Therapy, it was sug-
gested that thromboprophylaxis should not be used in
patients with isolated lower leg injuries, since it is
uncertain whether prophylaxis similarly reduces the
risk of clinically important VTE, or is cost-effective
[6]. A quantitative analysis of results from random-
ized trials was not presented. The results of a survey
of current practice on the use of thromboprophylaxis
during lower leg immobilization in the United King-
dom showed substantial variation among physicians,
and most of them were not aware of any existing
guidelines in this regard [7]. Therefore, a critical
analysis of the literature is warranted, considering
that below-knee/lower-leg immobilization is fre-
quently used in the treatment of Achilles tendon
ruptures, ligament sprains and lower leg fractures. In
this meta-analysis, we assess the effectiveness and
safety of pharmacological interventions for preventing
DVT or pulmonary embolism (PE) in patients with
below-knee/lower-leg immobilization due to a cast or
brace after an isolated lower leg injury.
Materials and Methods
Search Strategy to Identify Studies
The following electronic databases were searched:
PubMed, from 1966 to July 2007; EMBASE, from 1980
to July 2007; The Cochrane Central Register of Con-
trolled Trials (Clinical Trials). We constructed a topi-
cal search filter for PubMed and combined this topical
search filter with the broad, sensitive PubMed clinical
query for treatment. We also constructed a topical
search filter for EMBASE (appendix). In the Cochrane
Central Register of Controlled Trials, we searched for
‘‘leg injuries’’ and ‘‘thrombosis.’’ We also searched the
reference lists of the studies that were identified.
There were no restrictions on language. If the inclusion
criteria were met, full text articles were obtained
(Figure 1).
Selection of Studies
The titles and abstracts of the retrieved records were
checked by RM. Selection of records was based on the
following criteria: the records relate to (1) clinical trials
with (2) random allocation of pharmacological throm-
boprophylaxis (e.g., heparin, low molecular weight
heparin, coumarins and antiplatelet treatment) in (3)
ambulatory patients over 16 years old with (4) below-
knee or lower leg (i.e., including patients with immo-
bilized knee joints) immobilization after an isolated
lower leg injury in which (5) the outcomes were DVT
and PE. The selection was cross-checked by GH. Any
disagreements were resolved by a third author (EV).
Quality Assessment
The methodological quality of the trials included was
graded on six items, notably: randomization, conceal-
ment of allocation, blinding of treatment and end-
points, dropouts and completeness of data [10, 11]
(Table 1).
Data Extraction
The number of events and the number of patients
randomized for each treatment group in each trial were
extracted. Events included: prevention of proximal and
distal DVT by both clinical and diagnostic procedures,
i.e., venography or duplex/ultrasound; PE diagnosed by
V/Q lung scan, spiral computer tomography (CT),
pulmonary angiography or autopsy; death related to
embolic events. In addition, data on adverse events
were extracted, notably for major bleeding (i.e., re-
quired transfusion of red blood cells or surgical inter-
ventions) and minor bleeding (i.e., did not meet the
major criteria for intervention and bleeding-related
death). Data on baseline characteristics (i.e., risk fac-
tors for thrombosis [5, 10] and intervention character-
istics such as administration, dosage and duration)
were also extracted (Table 2, 3). Data extraction was
performed by one reviewer (RM) and cross-checked by
Pubmed:
Screened for 
retrieval (n = 102)
Retrieved for detailed 
evaluation (n = 13) 
Potentially appropriate 
RCT’s to be included (n = 7)
Excluded (n = 206) 
Reason: * 
Excludud (n = 6) 
Reason: ** 
RCT’s usable information by 
outcome (n = 5)
RCT’s excluded (n = 2) 
Reason: *** 
Embase:
Screened for 
retrieval (n = 85)
Cochrane:
Screened for 
retrieval (n = 34)
Figure 1. Flow diagram representing the search for and selection
of trials. *No lower leg immobilization/injuries, no ambulatory
patients/outpatients, nonpharmaceutical thromboprophylaxis, non-
randomized trials, overlap in databases. ** Duplicate data, selection
bias [23, 25–29]. ***Abstract only/insufficient data [20] or comparison
of two interventions with no control group [22]. Two studies were
retrieved by a manual reference search and were excluded after
detailed evaluation [21, 24].
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another (GH). Disagreements were resolved by con-
sensus discussion.
Statistical Analysis
The data analysis was performed using MIX [11] in
order to calculate the pooled risk ratio (RR) for each
outcome, along with its 95% confidence interval (CI),
according to the Mantel–Haenzel method. To over-
come the unwarranted exclusion of studies without an
event in both groups from the analysis, we added 0.001
events to the control group.
Results
Five trials met our search criteria [4, 12–15]. All five
trials compared thromboprophylaxis by low molecular
weight heparin to no prophylaxis or placebo. Patients
selected in these studies had isolated lower leg injuries
varying from ligament sprains to fractures. Three
studies (Kock, Kujath, Lapidus) used ultrasound/du-
plex to screen for DVT, while two studies (Jorgensen,
Lassen) used venography. Study characteristics are
given in Table 3. Importantly, two studies reported on
below-knee immobilization (Jorgensen, Lapidus), and
three studies reported on lower leg immobilization
(Kock, Kujath, Lassen). These last three studies in-
cluded patients with an immobilized knee joint as well.
Kock described the subgroup of patients with below-
knee immobilization separately in his report, and these
data were used for the analysis of VTE in below-knee
immobilization as well.
VTE in below-knee immobilization
The relative risk (RR) of asymptomatic DVT (proxi-
mal and distal) in below-knee immobilization after an
isolated lower leg injury (obtained by pooling data
from three studies with a total of 587 patients) is 0.66,
with a 95% CI from 0.44 to 1.02 favoring prophylaxis
(Jorgensen, Kock, Lapidus) (Figure 2). Low molecular
weight heparin (LMWH) versus no prophylaxis or
placebo was evaluated. The RR for asymptomatic
proximal DVT alone (obtained by pooling data from
three studies with a total of 640 patients) is 0.24 (95%
CI 0.05; 1.12) favoring prophylaxis (Jorgensen, Kock,
Lapidus) (Figure 3). The RR of asymptomatic DVT in
Achilles tendon rupture treatment (obtained by pool-
ing data from two studies with a total of 167 patients) is
0.73 (95% CI: 0.44; 1.21) favoring prophylaxis (Lapi-
dus, Lassen). In the studies on below-knee immobili-
zation, none of the participants suffered asymptomatic
DVT or PE (Jorgensen, Kock, Lapidus). Therefore, an
analysis of pooled data was not performed.
VTE in lower-leg immobilization
Kock, Kujath and Lassen reported on patients with
lower leg immobilization. Pooling their results with
those of Jorgensen and Lapidus (including 1,259 pa-
tients in total) resulted in a RR of asymptomatic DVT
for lower leg immobilization of 0.51 (95% CI: 0.37;
0.70) (Figure 4). As stated before, this RR concerns a
mixed group of patients with ankle joint (below-knee)
and/or knee joint immobilization.
The RR of symptomatic DVT in lower leg immo-
bilization (obtained by pooling data from three studies
with a total of 667 patients) is 0.28 (95% CI 0.05; 1.69)
favoring prophylaxis (Jorgensen, Lapidus, Lassen)
(Figure 5). In the study by Lassen, clinical signs of
DVT for each subgroup were described. In four out of
Table 2. Available baseline characteristics of the patients analyzed
(pooled).
Baseline characteristics (pooled) LMWH No prophylaxis
N 719 716
Male 405 (56%) 430 (60%)
Smoking 286 (40%) 299 (42%)
Oral contraceptives 47 (7%) 56 (8%)
Previous DVT/venous thromboembolism 17 (2%) 14 (2%)
Varicose veins 69 (10%) 88 (12%)
Table 1. Quality assessment of the included randomized clinical trials. (+: Reported to be performed; –: reported as not being performed; ?: not
reported/unknown. Missing data on DVT, obtained by a diagnostic procedure: +: reported and <10%; –: not reported or reported and >10%).
Study Randomization Concealment
of allocation
Blinding of
treatment
Blinding of
outcome
Withdrawals Missing
data
Jorgensen [12] + ? – + + –
Kock [13] + ? – – + –
Kujath [14] + ? – – + –
Lapidus [4] + ? + + + –
Lassen [15] + + + + + –
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11 patients with clinical suspicion of DVT, the diag-
nosis was confirmed by venography. All four patients
were in the placebo group. In the studies by Jorgensen
and Lapidus, none of the analyzed patients exhibited
any clinical sings of DVT. Kock and Kujath did not
report sufficiently on clinical DVT. The pooled abso-
lute risk of symptomatic DVT in the control group is
1.2 versus 0% in the prophylaxis group.
Lapidus
Kock
Jorgensen
0,001 0,01 0,1 1 10
RR (log scale)
Figure 2. The effect of low molecular weight heparin on asymp-
tomatic deep venous thrombosis in below-knee immobilization.
Lapidus
Kock
Jorgensen
0,001 0,01 0,1 1 10
RR (log scale)
Figure 3. The effect of low molecular weight heparin on proximal
asymptomatic deep venous thrombosis in below-knee immobiliza-
tion.
Lassen
Lapidus
Jorgensen
Kujath
Kock
0,001 0,01 0,1 1 10
RR (log scale)
Figure 4. The effect of low molecular weight heparin on asymp-
tomatic deep venous thrombosis in lower-leg immobilization.
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PE was confirmed by ventilation-perfusion scan
after clinical suspicion in two patients in the placebo
group in the study by Lassen. In two studies, there was
no clinical suspicion of PE in any of the patients
(Jorgensen, Lapidus). Therefore, the RR for PE is 0.44
(95% CI 0.06; 2.94) favoring prophylaxis, including
three studies with a total of 843 patients (Figure 4).
Adverse events (in lower leg immobilization)
Adverse events are reported in all studies (Jorgensen,
Kock, Kujath, Lapidus, Lassen). The RR for any ad-
verse event in lower leg immobilisation is 1.94 (95% CI
1.03; 3.67) favouring no prophylaxis or placebo,
including five studies with a total of 1,435 patients
(Figure 6). One bleeding event (retroperitoneal bleed)
described in the study by Lassen is considered to be
major. All other bleeding events were minor (e.g., nose
bleed, hematoma at injection site). Seven patients
discontinued the allocated study medication (LMWH
of placebo) due to minor bleeding; one due to
metrorrhagia. None of the studies reported deaths.
None of the studies reported any change in platelet
count or signs of heparin-induced thrombopenia.
Discussion
The 34% RR reduction in asymptomatic DVT in pa-
tients with below-knee immobilization using LMWH
and the 76% RR reduction in potentially more
dangerous proximal asymptomatic DVT are not sta-
tistically significant. The 49% RR reduction in
asymptomatic DVT in patients with lower-leg immo-
bilization is. However, the aim of thromboprophylaxis
is to prevent symptomatic VTE (i.e., symptomatic
DVT and post-thrombotic syndrome, PE and death by
thromboembolic event). The incidence of symptomatic
DVT after pooling data is 1.2% and is too low to show
a statistically significant difference between groups.
Much larger numbers are needed to clearly identify the
benefit of prophylaxis (it was impossible to pool the
results for symptomatic DVT and PE, as more patients
were available for the outcome of PE). Still, asymp-
tomatic DVT is accepted as a surrogate endpoint for
VTE in hip and knee surgery [16, 17]. A parallel
reduction in the relative risk of asymptomatic DVT
and symptomatic VTE is found when thrombopro-
phylaxis is used in these patient categories [19]. If this
parallel reduction also exists in below-knee immobili-
zation, a 49% reduction in a 1.2% absolute symptom-
atic DVT risk would mean treating over 150 patients to
prevent one symptomatic DVT. The number that
would be needed to be treated to prevent a PE would
be much higher. But is the 1.2% symptomatic DVT
risk realistic? In trials where DVT screening is used,
knowledge of the results of these screening tests can
affect the true incidence of symptomatic DVT (and
VTE) due to diagnostic decision bias [16]. None of the
studies included in our analysis reported the number of
patients treated. Mizel’s study did not use screening
methods and found a < 1% incidence of symptomatic
DVT in patients after foot or ankle surgery with
postoperative immobilization [3]. These results also
suggest that the incidence of symptomatic DVT and
(even more so) PE is probably very low. We cannot
explain the high incidence of DVT reported by Lapi-
dus, as the data from that investigation are unpublished
[4]. The studies included provide indirect evidence for
a large effect (RR reduction) of thromboprophylaxis
on symptomatic VTE in lower leg immobilization. This
effect of prophylaxis is not doubted; a clinically rele-
vant effect of thromboprophylaxis on the incidence of
symptomatic DVT or PE in patients with lower leg
immobilization is questionable though, and probably
even more so in below-knee immobilization. The
incidence of symptomatic VTE seems too low to
legitimize the routine use of prophylaxis. The results
from our meta-analysis do show that thromboprophy-
Lassen
Lapidus
Kujath
Kock
Jorgensen
0,01 0,1 1 10 100 1000
RR (log scale)
Figure 6. The effect of low molecular weight heparin on all adverse
events in lower-leg immobilization.
Lassen
Lapidus
Jorgensen
0,001 0,01 0,1 1 10 100
RR (log scale)
Figure 5. The effect of low molecular weight heparin on symptom-
atic DVT in lower leg immobilization.
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laxis using LMWH can be considered to be safe. Al-
though thromboprophylaxis significantly increases the
RR of adverse bleeding events, these events were all
minor, except for one retroperitoneal bleed.
The results of this meta-analysis itself deserve some
further considerations too. First, the number of studies
included is limited, while the allocation of concealment
and the completeness of the data analyzed are reported
in an insufficient manner. There were several patients
in the included studies for whom outcome could not be
determined. The main reasons for missing outcome
values were patients’ refusal of venography or the
technical impossibility of venography. 83% of the ran-
domized patients were used in the analysis to calculate
the RR for asymptomatic DVT, as the outcomes were
unknown for the others. Most of these patients were not
lost to follow-up and so were included in the analysis of
risk of PE and adverse events.
Second, a variation in baseline risk across clinical
trials included in a meta-analysis is common, and may
have an impact on the benefits of treatment for indi-
vidual patients [18]. The studies included varied in
terms of the risk factors for thrombosis, such as type of
injury, operation, hospitalization, and duration and
type of immobilization. A rigid non-weight-bearing cast
with knee joint immobilization is considered a bigger
risk for the development of thrombosis than nonrigid
weight-bearing below-knee immobilization [5]. In-
creased age and age-related (co)morbidities are con-
sidered to be risk factors as well [10], but age was
consistent at baseline across studies. Furthermore, as no
trials on the use of coumarins for the prevention of
VTE were found, no conclusions can be drawn
regarding the efficacy and safety of this antithrombotic
agent. Finally, venography is considered the gold
standard diagnostic test for DVT, but has largely been
replaced by ultrasonographic modalities [19]. Kock,
Kujath and Lapidus use ultrasound to measure out-
come; if DVT is suspected, venography is performed.
According to the study protocol, Kock verified all of the
DVTs venographically. Kujath reported that 22 out of
the 27 DVTs seen during compression ultrasound could
be verified venographically. Lapidus verified all of the
DVTs venographically except for two proximal DVTs,
because duplex sonography was considered to exhibit
high sensitivity and specificity for proximal DVT.
In conclusion, there is insufficient evidence for the
routine use of thromboprophylaxis in ambulatory pa-
tients with below-knee or lower leg immobilization
after an isolated lower-leg injury. Future studies should
include large numbers of patients with a stratification
of risk factors; only this would make it possible to find
a selected patient group that can clearly benefit from
pharmacological thromboprophylaxis during the
immobilization of an injured leg.
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